A Double Blind Randomized Trial to Compare the Effects of Eprosartan and Enalapril on Blood Pressure, Platelets, and Endothelium Function in Patients With Essential Hypertension

スポンサーリンク

概要

• 論文の詳細を見る

• The renin-angiotensin system is the major contributor to development of hypertension, atherosclerosis, and many other cardiovascular diseases. Angiotensin II, one of the main effectors of this system, contributes to the pathogenesis of hypertension and plays an important role in monocyte, platelet, and endothelium interactions. The effects on platelet and endothelial function, either by angiotensin converting enzyme inhibitors or angiotensin receptor antagonists, are still not well understood. A double-blind, randomized, prospective trial of either enalapril (10-20 mg daily) or eprosartan (400-800 mg daily) over a 10-week period was conducted in 42 patients (27 males, 15 females). Platelet activation was evaluated by measuring platelet factor 4 (PF-4), beta-thromboglobulin (β-TG), the ratio of platelet factor 4 to beta-thromboglobulin, and endothelial function by measuring total plasma nitrate levels, von Willebrand factor (vWF) levels, and blood flow using venous occlusive plethysmography. After a 10-week treatment with enalapril or eprosartan, the sitting blood pressure in both the enalapril group (from 152.2 ± 18.7 mmHg to 141.9 ± 23.5 mmHg, P < 0.05) and eprosartan group (from 151 ± 10.0 mmHg to 142.3 ± 12.9 mmHg, P < 0.05) was significantly reduced. Significant diastolic blood pressure (DPB) reduction (from 94 ± 8.7 to 84.5 ± 9.6 mmHg, P < 0.05) and a greater DBP reduction response were found in the eprosartan group (63% in eprosartan versus 25% in enalapril). Additionally, dose-dependent reductions in the indices of platelet activation and endothelial dysfunction were observed in patients administered high dose treatments of eprosartan and enalapril, and the beneficial effects of these agents were not correlated with the reduction of blood pressure using both agents. Eprosartan is effective and well-tolerated in the treatment of mid-to-moderate hypertension, and the DBP response reduction to eprosartin was better than that to enalapril. A high dose of either eprosartan or enalapril significantly decreased the indices of platelet activation and endothelial dysfunction in hypertensive patients. The benefits of both agents cannot be explained solely by their antihypertensive effects and possibly may be mediated through their unique effect on angiotensin blockade.

著者

• Leu Hsin-bang

  Division Of Cardiology Taipei Veterans General Hospital

• Ding Philip

  Division of Cardiology, Taipei Veterans General Hospital and National Yang-Ming University

• Leu Hsin-Bang

  Division of Cardiology, Taipei Veterans General Hospital and National Yang-Ming University

• Charng Ming-Ji

  Division of Cardiology, Taipei Veterans General Hospital and National Yang-Ming University

関連論文

• A Double Blind Randomized Trial to Compare the Effects of Eprosartan and Enalapril on Blood Pressure, Platelets, and Endothelium Function in Patients With Essential Hypertension
• Decreased circulating endothelial progenitor cell levels and function in essential hypertensive patients with electrocardiographic left ventricular hypertrophy
• Angiotensin-Receptor Blockers and Risk of Alzheimer’s Disease in Hypertension Population : – A Nationwide Cohort Study –
• Increased Risk of Gastrointestinal Malignancy in Patients with Diabetes Mellitus and Correlations with Anti-Diabetes Drugs: A Nationwide Population-based Study in Taiwan
• Increased Risk of Ischemic Stroke in Patients with Systemic Lupus Erythematosus: A Nationwide Population-based Study
• Association of Tamoxifen Use and Reduced Cardiovascular Events Among Asian Females With Breast Cancer
• Angiotensin-Receptor Blockers and Risk of Alzheimer's Disease in Hypertension Population : A Nationwide Cohort Study

スポンサーリンク